514 / 604
Author/year
Design # mCRC pts. Lung/liver/LN Fract x dose
Local control
2 years
Survival
2 years
Lee 2009
Phase I
40/68
0/40/0
3 x 9.2-‐20Gy
(NTCP-‐based)
(-‐)
35%
Van der Pool 2010 Phase I/II
20
0/20/0
3 x 12.5Gy
74%
83%
Kang 2010
Retrospect
59
13/10/31
3 x 12-‐17Gy
65%
65%
Chang 2011
Phase I/II
65
0/65/0
1x22-‐3x20 Gy
55%
38%
Bae 2012
Retrospect
41
12/11/18
3 x 15-‐20 Gy
76%
68%
Van den Begin
2014
Retrospect
47
NA
4-‐5 x 10 Gy
(isocenter)
53%(lung/liver)
79% (LN) 1-‐year
65%*
Filippi 2014
Retrospect
40
40/0/0
1 x 26-‐4 x 12 Gy
NA
73%
Comito 2014
Phase II
82
60/52/0
4 x 12-‐3 x 25Gy
80%
65%
Thibault 2014
Retrospect
45/83
4 x 12-‐20 Gy
76%
72%*
De Vin 2014
Retrospect
103/309
56/77/176
10 x 4-‐5 Gy
33%
32% (3-‐year)
Takahachi 2014
Carbon ions
Feasibility
34
34/0/0
4 x 13.2-‐15 GyE
85%
65%
Qiu 2015
Retrospect
64
42/NA/NA 10x5Gy or 5x10Gy
31%
43%
Fode 2015
Retrospect
201
30/165/6
3 x 15-‐22.5 Gy
(isocenter)
LR: 13%
58%
Phase II or retrospec+ve cohorts
mCRC: Local control rates 31-‐85%